Depakote ER in Borderline Personality Disorder

University of Minnesota15 enrolled

Overview

This study examines the effect of Depakote ER versus placebo in a randomized trial of borderline personality disorder. Patients all participate in DBT therapy and those who are not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline Personality Symtoms are measured and side-effects are assessed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Borderline Personality Disorder

Interventions

Depakote ERDRUG

Eligibility

Sex: ALLMin age: 21 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria:Male or female patients with the diagnosis of borderline personality disorder between the ages of 21 adn 55 years old. Must be in good physical health - Exclusion Criteria:Major psychiatric illness on Axis I - schizophrenia or bipolar disorder. May not have current MDD. May not be dependent on illicit substances or alcohol. \-

Outcomes

Primary Outcomes

Symptom Checklist 90

Secondary Outcomes

Barratt Impulsivity Scale

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.